The EndoSleeve is a proprietary implant anchors at the junction of the stomach and small intestine (the pyloric sphincter). The sleeve component of the implant channels food from the stomach and bypasses a portion of the small intestine. Because the food is blocked from contacting the intestine, nuero-hormonal signaling is altered. This quickly leads to the remission of Type 2 Diabetes and eventually weight loss.
The procedure doctors use to place the EndoSleeve is similar to a routine GI endoscopy and can be performed under conscious sedation. The tools and techniques involved are familiar to gastroenterologists, endoscopic surgeons, and interventional radiologists. The procedure will take less than 30 minutes to perform and the patient will be able to return home the same day.
In the past 10 years, researchers discovered that gastric bypass surgery, in which a portion of the stomach and small intestine is bypasses, results in remission of T2DM in addition to the expected weight loss. This breakthrough has provided a meaningful alternative for obese patients struggling to manage their diabetes. The American Diabetes Association now recommends gastric bypass surgery as a treatment option for patients with diabetes
Unfortunately, the benefits provided by this procedure are limited to only a fraction of people living with Type 2 Diabetes. Currently, bariatric surgery is reserved for only morbidly obese patients due to the fact that is risky (0.5% - 2% mortality), expensive ($35,000), and invasive (1 week hospital stay and lifelong changes in diet) and